Cipla invests $90 million in API plants; Isis gets EMA nod for California plant;

> In its annual report, India-based Cipla says it will invest about $89.9 million to build active pharmaceutical ingredients (API) facilities at Patalganga, Mumbai, Bengaluru, Karnataka, and Kurkumbh, Pune, India. Annual report

> The Medicines and Healthcare Products Regulatory Agency in the U.K. has updated its 45-year-old regulations over drug manufacturing and distribution. Story

> An Isis Pharmaceuticals plant in Carlsbad, CA, has received EMA approval in anticipation of launch in Europe of Kynamro, a lipid-lowering drug it is developing with Genzyme. Story

> Materia has extended for another decade an agreement with Sigma-Aldrich for global distribution of its catalyst technology. Item

And Finally... Japanese regulators have approved for distribution in Japan Teijin's Bonalon Jelly, the first time the osteoporosis drug has been manufactured in this form, the company says. Release

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.